Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Globe Newswire•01/10/2026•08:25 ET
0
Key Highlights
- ➤PCT/US2026/45955 expands Akari Therapeutics (AKTX) PH1 payload patent portfolio
- ➤PH1 altered VEGF-A splicing toward anti-angiogenic VEGF-165b isoform
- ➤PH1 altered FAS splicing, increasing cancer-cell susceptibility to immune-mediated death
- ➤AKTX-101 IND-enabling studies target first-in-human trial by mid-2027
Expert Statements
Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics
“This PCT filing represents another important expansion of our intellectual property portfolio and further demonstrates the differentiated potential of PH1 as a novel ADC payload with unique properties vs. current ADC payloads. These claims illustrate PH1’s potential to impact multiple fundamental mechanisms that cancer tumors use to survive and spread, including angiogenesis, oncogene signaling and avoiding programmed cell death. We believe the breadth of this biology further supports the potential of PH1 as a platform payload for the development of differentiated ADCs across multiple tumor targets and cancer types. As we continue to expand our understanding of PH1, we are building an increasingly robust intellectual property foundation for our novel PH1 payload and ADC portfolio.”
Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism
Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform
Get started
Create a free account to read the full story.